174 related articles for article (PubMed ID: 17515697)
1. Persistence with once-daily versus twice-daily bupropion for the treatment of depression in a large managed-care population.
Stang P; Suppapanaya N; Hogue SL; Park D; Rigney U
Am J Ther; 2007; 14(3):241-6. PubMed ID: 17515697
[TBL] [Abstract][Full Text] [Related]
2. Better patient persistence with once-daily bupropion compared with twice-daily bupropion.
Stang P; Young S; Hogue S
Am J Ther; 2007; 14(1):20-4. PubMed ID: 17303971
[TBL] [Abstract][Full Text] [Related]
3. Once-daily bupropion associated with improved patient adherence compared with twice-daily bupropion in treatment of depression.
McLaughlin T; Hogue SL; Stang PE
Am J Ther; 2007; 14(2):221-5. PubMed ID: 17414593
[TBL] [Abstract][Full Text] [Related]
4. An assessment of patient preference and adherence to treatment with Wellbutrin SR: a web-based survey.
Granger AL; Fehnel SE; Hogue SL; Bennett L; Edin HM
J Affect Disord; 2006 Feb; 90(2-3):217-21. PubMed ID: 16360216
[TBL] [Abstract][Full Text] [Related]
5. Bupropion extended-release for depressive disorders.
Jefferson JW
Expert Rev Neurother; 2008 May; 8(5):715-22. PubMed ID: 18457528
[TBL] [Abstract][Full Text] [Related]
6. Bupropion sustained release: a therapeutic overview.
Davidson JR; Connor KM
J Clin Psychiatry; 1998; 59 Suppl 4():25-31. PubMed ID: 9554318
[TBL] [Abstract][Full Text] [Related]
7. Seasonal affective disorder and its prevention by anticipatory treatment with bupropion XL.
Modell JG; Rosenthal NE; Harriett AE; Krishen A; Asgharian A; Foster VJ; Metz A; Rockett CB; Wightman DS
Biol Psychiatry; 2005 Oct; 58(8):658-67. PubMed ID: 16271314
[TBL] [Abstract][Full Text] [Related]
8. Bupropion sustained release: side effect profile.
Settle EC
J Clin Psychiatry; 1998; 59 Suppl 4():32-6. PubMed ID: 9554319
[TBL] [Abstract][Full Text] [Related]
9. Effect of bupropion SR on specific symptom clusters of depression: analysis of the 31-item Hamilton Rating Scale for depression.
Jamerson BD; Krishnan KR; Roberts J; Krishen A; Modell JG
Psychopharmacol Bull; 2003; 37(2):67-78. PubMed ID: 14566216
[TBL] [Abstract][Full Text] [Related]
10. An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners.
Moss EL; Simpson JS; Pelletier G; Forsyth P
Psychooncology; 2006 Mar; 15(3):259-67. PubMed ID: 16041840
[TBL] [Abstract][Full Text] [Related]
11. Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations.
Jefferson JW; Pradko JF; Muir KT
Clin Ther; 2005 Nov; 27(11):1685-95. PubMed ID: 16368442
[TBL] [Abstract][Full Text] [Related]
12. Factors contributing to compliance with osteoporosis medication.
Kertes J; Dushenat M; Vesterman JL; Lemberger J; Bregman J; Friedman N
Isr Med Assoc J; 2008 Mar; 10(3):207-13. PubMed ID: 18494234
[TBL] [Abstract][Full Text] [Related]
13. Effect of medication burden on persistent use of lipid-lowering drugs among patients with hypertension.
Robertson TA; Cooke CE; Wang J; Shaya FT; Lee HY
Am J Manag Care; 2008 Nov; 14(11):710-6. PubMed ID: 18999905
[TBL] [Abstract][Full Text] [Related]
14. Bupropion-SR in treatment of social phobia.
Emmanuel NP; Brawman-Mintzer O; Morton WA; Book SW; Johnson MR; Lorberbaum JP; Ballenger JC; Lydiard RB
Depress Anxiety; 2000; 12(2):111-3. PubMed ID: 11091936
[TBL] [Abstract][Full Text] [Related]
15. A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients.
Reimherr FW; Cunningham LA; Batey SR; Johnston JA; Ascher JA
Clin Ther; 1998; 20(3):505-16. PubMed ID: 9663366
[TBL] [Abstract][Full Text] [Related]
16. The impact of bupropion on psychomotor performance.
Paul MA; Gray G; Kenny G; Lange M
Aviat Space Environ Med; 2002 Nov; 73(11):1094-9. PubMed ID: 12433233
[TBL] [Abstract][Full Text] [Related]
17. Economic impact of non-persistence to antidepressant therapy in the Quebec community-dwelling elderly population.
Tournier M; Moride Y; Crott R; du Fort GG; Ducruet T
J Affect Disord; 2009 May; 115(1-2):160-6. PubMed ID: 18694602
[TBL] [Abstract][Full Text] [Related]
18. Varenicline and bupropion sustained-release combination therapy for smoking cessation.
Ebbert JO; Croghan IT; Sood A; Schroeder DR; Hays JT; Hurt RD
Nicotine Tob Res; 2009 Mar; 11(3):234-9. PubMed ID: 19246427
[TBL] [Abstract][Full Text] [Related]
19. A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia.
Evins AE; Cather C; Culhane MA; Birnbaum A; Horowitz J; Hsieh E; Freudenreich O; Henderson DC; Schoenfeld DA; Rigotti NA; Goff DC
J Clin Psychopharmacol; 2007 Aug; 27(4):380-6. PubMed ID: 17632223
[TBL] [Abstract][Full Text] [Related]
20. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
Sun SX; Ye X; Lee KY; Dupclay L; Plauschinat C
Clin Ther; 2008; 30 Pt 2():2217-27. PubMed ID: 19281916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
